The inaugural virtual Prostate Cancer Drug Development Summit is the first dedicated conference for large pharma, biotech and pioneering academics to unite under a common and ambitious goal of accelerating the practical discovery, translation, and clinical development of safe and effective treatments for prostate cancer.
Here's a sneak peek of crucial topics to be addressed and you shouldn't miss:
• Exploring the role of immunotherapy for the treatment of prostate cancer
• Bringing theranostics to prostate cancer
• Optimizing strategies for overcoming the immunosuppressive prostate tumor microenvironment
• Assessing opportunities and challenges for T-cell directed therapies in prostate cancer
• Examining next-generation small molecule inhibitors, degraders of androgen receptor (AR) and AR-splice variants
Join 80+ thought-leaders with the likes of Amgen, Bristol-Myers Squibb, Novartis, Noxopharm, and many more, and leave this meeting with the latest scientific insights from renowned Urologists/Oncologists striving to advance safe and effective therapeutic breakthroughs to patients in need.
For more information visit: www.prostatecancer-drugdevelopment.com